Cochlear Ltd (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$11.78 billion
P/E Ratio
36.51
Dividend Yield
2.23%
Shares Outstanding
65.40 million
Earnings per share
5.275
Dividend per share
4.30
Year To Date Return
-28.71%
Earnings Yield
2.74%
Franking
85
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Ltd (ASX: COH)
Latest News
Growth Shares
Experts say these are the ASX 200 shares to buy next week
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
3 ASX 200 companies that could benefit from a falling Aussie dollar
Healthcare Shares
Move over gold: Could ASX 200 healthcare shares be the new 'safe-haven' investments?
Share Market News
Here are the top 10 ASX 200 shares today
Share Market News
Not all ASX 200 shares are getting hammered today. Here are some winners
Growth Shares
Here are 3 top ASX growth shares that analysts rate as buys
Healthcare Shares
Why is the Cochlear share price slipping on Wednesday?
Dividend Investing
Here's how to grab your piece of the latest Cochlear dividend
Dividend Investing
Here are 3 ASX 200 shares turning ex-dividend tomorrow
Healthcare Shares
ASX 200 better buy: Cochlear or CSL shares?
Broker Notes
Goldman Sachs says these ASX shares are flying under the radar post-results
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year. From October 2019, dividends were unfranked until October 2022 when dividends were 40% franked.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 18 Sep 2025 | $2.1500 | 85.00% | Final | 13 Oct 2025 |
| 20 Mar 2025 | $2.1500 | 80.00% | Interim | 14 Apr 2025 |
| 17 Sep 2024 | $2.1000 | 80.00% | Final | 10 Oct 2024 |
| 21 Mar 2024 | $2.0000 | 70.00% | Interim | 15 Apr 2024 |
| 18 Sep 2023 | $1.7500 | 70.00% | Final | 11 Oct 2023 |
| 21 Mar 2023 | $1.5500 | 35.00% | Interim | 14 Apr 2023 |
| 21 Sep 2022 | $1.4500 | 40.00% | Final | 17 Oct 2022 |
| 28 Mar 2022 | $1.5500 | 0.00% | Interim | 21 Apr 2022 |
| 23 Sep 2021 | $1.4000 | 0.00% | Final | 18 Oct 2021 |
| 25 Mar 2021 | $1.1500 | 0.00% | Interim | 20 Apr 2021 |
| 19 Sep 2019 | $1.7500 | 100.00% | Final | 14 Oct 2019 |
| 25 Mar 2019 | $1.5500 | 100.00% | Interim | 16 Apr 2019 |
| 17 Sep 2018 | $1.6000 | 100.00% | Final | 10 Oct 2018 |
| 19 Mar 2018 | $1.4000 | 100.00% | Interim | 12 Apr 2018 |
| 19 Sep 2017 | $1.0000 | 100.00% | Final | 11 Oct 2017 |
| 15 Mar 2017 | $1.3000 | 100.00% | Interim | 06 Apr 2017 |
| 07 Sep 2016 | $1.2000 | 100.00% | Final | 29 Sep 2016 |
| 10 Mar 2016 | $1.1000 | 100.00% | Interim | 01 Apr 2016 |
| 02 Sep 2014 | $1.2700 | 20.00% | Final | 25 Sep 2014 |
| 20 Feb 2006 | $0.4500 | 100.00% | Interim | 14 Mar 2006 |
| 26 Aug 2005 | $0.4500 | 100.00% | Final | 22 Sep 2005 |
| 19 Feb 2004 | $0.3500 | 100.00% | Interim | 17 Mar 2004 |
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Ltd
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
COH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Mar 2026 | $180.06 | $-4.94 | -2.67% | 208,953 | $183.08 | $183.76 | $180.06 |
| 05 Mar 2026 | $185.00 | $-0.83 | -0.45% | 282,700 | $188.63 | $189.99 | $185.00 |
| 04 Mar 2026 | $185.83 | $-6.79 | -3.53% | 330,168 | $192.87 | $192.88 | $185.83 |
| 03 Mar 2026 | $192.62 | $-3.08 | -1.57% | 200,340 | $195.00 | $195.57 | $192.01 |
| 02 Mar 2026 | $195.70 | $-3.31 | -1.66% | 189,324 | $197.00 | $202.19 | $195.32 |
| 27 Feb 2026 | $199.01 | $0.34 | 0.17% | 571,620 | $198.00 | $203.70 | $195.84 |
| 26 Feb 2026 | $198.67 | $1.67 | 0.85% | 253,168 | $197.44 | $200.74 | $195.14 |
| 25 Feb 2026 | $197.00 | $4.00 | 2.07% | 248,706 | $191.60 | $197.00 | $191.11 |
| 24 Feb 2026 | $193.00 | $-2.40 | -1.23% | 256,137 | $194.95 | $196.70 | $191.51 |
| 23 Feb 2026 | $195.40 | $-3.36 | -1.69% | 159,798 | $199.21 | $201.00 | $195.40 |
| 20 Feb 2026 | $198.76 | $-1.18 | -0.59% | 203,113 | $199.00 | $202.00 | $194.70 |
| 19 Feb 2026 | $199.94 | $2.08 | 1.05% | 210,623 | $198.01 | $201.85 | $197.10 |
| 18 Feb 2026 | $197.86 | $-1.95 | -0.98% | 222,690 | $201.50 | $203.33 | $197.33 |
| 17 Feb 2026 | $199.81 | $-0.69 | -0.34% | 256,255 | $201.25 | $204.43 | $198.10 |
| 16 Feb 2026 | $200.50 | $1.28 | 0.64% | 353,484 | $202.30 | $205.73 | $197.76 |
| 13 Feb 2026 | $199.22 | $-46.42 | -18.90% | 394,092 | $220.01 | $221.67 | $198.50 |
| 12 Feb 2026 | $245.64 | $-9.15 | -3.59% | 157,551 | $250.57 | $254.70 | $242.93 |
| 11 Feb 2026 | $254.79 | $-2.11 | -0.82% | 75,224 | $256.78 | $257.35 | $253.50 |
| 10 Feb 2026 | $256.90 | $3.78 | 1.49% | 87,651 | $254.66 | $257.43 | $253.53 |
| 09 Feb 2026 | $253.12 | $2.95 | 1.18% | 107,415 | $250.95 | $253.12 | $247.87 |
| 06 Feb 2026 | $250.17 | $-8.57 | -3.31% | 184,907 | $258.14 | $258.49 | $246.13 |
| 05 Feb 2026 | $258.74 | $-1.27 | -0.49% | 105,166 | $260.44 | $261.08 | $257.20 |
| 04 Feb 2026 | $260.01 | $-6.75 | -2.53% | 136,931 | $264.00 | $266.67 | $258.34 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Feb 2026 | Bruce Robinson AC | Buy | 253 | $50,149 |
On-market trade.
|
| 18 Feb 2026 | Karen Penrose | Buy | 100 | $20,122 |
On-market trade.
|
| 16 Feb 2026 | Richard Freudenstein | Buy | 485 | $98,750 |
On-market trade.
|
| 02 Sep 2025 | Dig Howitt | Sell | 849 | $254,708 |
On-market trade.
|
| 29 Aug 2025 | Dig Howitt | Sell | 3,101 | $935,261 |
As advised by the company. NO NOC
|
| 29 Aug 2025 | Dig Howitt | Exercise | 3,950 | $918,454 |
Exercise of options.
|
| 29 Aug 2025 | Dig Howitt | Issued | 3,950 | $918,454 |
Exercise of options.
|
| 28 Aug 2025 | Michael del Prado | Buy | 75 | $15,000 |
On-market trade. USD$
|
| 27 Aug 2025 | Caroline Clarke | Buy | 60 | $18,052 |
On-market trade.
|
| 22 Aug 2025 | Caroline Clarke | Buy | 135 | $40,830 |
On-market trade.
|
| 21 Aug 2025 | Dig Howitt | Sell | 1,500 | $453,450 |
On-market trade.
|
| 21 Aug 2025 | Caroline Clarke | Buy | 43 | $12,929 |
On-market trade.
|
| 18 Aug 2025 | Dig Howitt | Sell | 5,457 | $1,625,203 |
As advised by the company. Sales of Shares to fund excercise of options
|
| 18 Aug 2025 | Dig Howitt | Exercise | 6,954 | $1,616,944 |
Exercise of options.
|
| 18 Aug 2025 | Dig Howitt | Issued | 2,670 | $791,281 |
Conversion of securities.
|
| 18 Aug 2025 | Dig Howitt | Issued | 6,954 | $1,616,944 |
Exercise of options.
|
| 18 Aug 2025 | Dig Howitt | Exercise | 2,670 | $791,281 |
Conversion of securities.
|
| 18 Aug 2025 | Dig Howitt | Exercise | 2,670 | $791,281 |
Conversion of securities. 24663 Rights
|
| 18 Aug 2025 | Dig Howitt | Issued | 2,670 | $791,281 |
Conversion of securities.
|
| 18 Aug 2025 | Dig Howitt | Issued | 6,954 | $1,616,944 |
Exercise of options.
|
| 18 Aug 2025 | Dig Howitt | Expiry | 10,904 | $3,231,509 |
Options expired.
|
| 18 Aug 2025 | Dig Howitt | Expiry | 2,671 | $791,577 |
As advised by the company. lapsed, 21992 rights
|
| 18 Aug 2025 | Dig Howitt | Exercise | 6,954 | $1,616,944 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Christine Frances McLoughlin | Non-Executive Director | Nov 2020 |
Ms McLoughlin has experience as a director on the boards of ASX Top 50 Companies in financial services (including banking, life insurance, superannuation, asset management and general insurance), resources, health insurance and infrastructure sectors over the past 15 years. She has been active in the not-for-profit sector over her entire career. Chairman of Suncorp Group Limited and Aware Super. Co-founder and Chairman of the Minerva Network. She is Chair of the People and Culture Committee and a member of the Risk Product and Services Innovation Committees.
|
| Sir Michael Grenfell Daniell | Non-Executive Director | Jan 2020 |
Sir Daniell has over 40 years of experience in the medical device industry with executive leadership experience. Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. He is part of other boards: Director, Fisher & Paykel Healthcare Corporation Ltd. Director, Tait International Limited. Director, Medical Research Commercialization Fund. He is Chair of the Product and Services Innovation Committee and a member of the Risk and Medical Science Committees.
|
| Ms Catriona Alison Deans | Non-Executive DirectorNon-Executive Chairman | Jan 2015 |
Ms Deans has experience leading technology-enabled businesses across e-commerce, media and financial services. A former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand.
|
| Ms Karen Lee Collett Penrose | Non-Executive Director | Jul 2022 |
Ms Penrose has an executive career in senior leadership and Chief Financial Officer roles in financial services. An experienced company director, who has served on the boards of several companies and experienced across health care, financial services, property and infrastructure industries. Other boards: Director, Ramsay Health Care Limited, Bank of Queensland Limited and Charter Hall Group. Director, Ramsay General De Sante (associated with directorship of Ramsay Health Care Limited), Marshall Investments Pty Limited, NSW Waratahs Ltd and Waratahs Rugby Pty Ltd. She is Chair of the Risk Committee and is a Member of the People and Culture and Product and Services Innovation Committees.
|
| Mr Richard John Freudenstein | Non-Executive Director | Aug 2025 |
Mr Freudenstein is a Non-executive Director of REA Group Limited (where he was Chairman from 2007 to 2012) and Coles Group Limited. He is the Chairman of Appen Limited, a board member of Cricket Australia and Deputy Chancellor of the University of Sydney. Previously, he was a Non-executive Director of Ten Network Holdings Ltd and Astro Malaysia Holdings Berhad. He has held the roles of Chief Executive Officer at Foxtel, News Digital Media and The Australian, and was Chief Operating Officer at British Sky Broadcasting.
|
| Professor Bruce Gregory Robinson AC | Non-Executive Director | Dec 2016 |
Mr Robinson has over 20 years of leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Co-Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research and Chair of Research, North Sydney Local Health District. Deputy Chairman (former Chairman), Hoc Mai Foundation. Senior Advisor to McKinsey & Company and Advisor to MinterEllison. He is Chair of Medical Science Committee and a member of the Risk Product and Services Innovation Committees.
|
| Mr Dig Howitt | PresidentChief Executive OfficerManaging Director | Jul 2017 |
Mr Howitt joined Cochlear in 2000 and has experience across the Company in roles including Chief Operating Officer, President, Asia Pacific and SVP, Manufacturing and Logistics. Prior to joining Cochlear, worked for Boston Consulting Group and held a General Management role at Boral. He was appointed as President of Cochlear on 31 July 2017 and became CEO & President on 3 January 2018. He is a Member of the Medical Science and Product and Services Innovation Committees. He is a member of the Medical Science and Product and Services Innovation Committees.
|
| Mr Michael del Prado | Non-Executive Director | Jan 2022 |
Mr Del Prado has over 38 years of global experience in the medical device and pharmaceutical industries with senior executive leadership roles in Johnson & Johnson medical device businesses in the US, Asia-Pac and EMEA. Former Company Group Chairman of Ethicon. He is a member of the People and Culture and Product and Services Innovation Committees.
|
| Ms Caroline Louise Clarke | Non-Executive Director | Sep 2024 |
Ms Clarke has commercial experience, including 20 years of executive leadership roles at medical devices, medical equipment and healthcare services businesses in large global companies. Former CEO and Executive Vice President ASEAN Pacific for Philips, where she was responsible for the overall strategy, business and management of the Health Systems and Consumer Personal Health businesses in 14 countries across the region. She is a Member of the People and Culture, Product and Services Innovation Committees.
|
| Ms Kristy Jo | Company Secretary | Apr 2024 |
-
|
| Mr Rob McGrory | Company Secretary | Apr 2024 |
-
|
| Dr Sarah Thom | Chief Financial Officer |
-
|
|
| Karen O'Driscoll | Chief Information Officer |
-
|
|
| Jan Janssen | Chief Technology Officer |
-
|
|
| Kristy Jo | Company Secretary |
-
|
|
| Rob McGrory | Company Secretary |
-
|
|
| Rob McGrory | Group General Counsel & Company Secretary |
-
|
|
| Stu Sayers | President Asia Pacific & Latin America |
-
|
|
| Anthony Bishop | President Europe Middle East and Africa (EMEA) |
-
|
|
| Lisa Aubert | President North America |
-
|
|
| Brian Kaplan | Senior Vice President Global Clinical Strategy and Innovation |
-
|
|
| Jennifer Hornery | Senior Vice President Global People & Culture |
-
|
|
| Dean Phizacklea | Senior Vice President Global Strategic Marketing |
-
|
|
| Greg Bodkin | Senior Vice President Global Supply Chain |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 26,204,019 | 40.07% |
| J P Morgan Nominees Australia Pty Limited | 10,892,062 | 16.66% |
| Citicorp Nominees Pty Limited | 8,430,442 | 12.89% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 1,830,219 | 2.80% |
| BNP Paribas Noms Pty Ltd | 1,469,118 | 2.25% |
| National Nominees Limited | 1,129,817 | 1.73% |
| HSBC Custody Nominees (Australia) Limited <NTComnwlth Super CORP A/C> | 469,415 | 0.72% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 454,099 | 0.69% |
| Australian Foundation Investment Company Limited | 433,174 | 0.66% |
| Netwealth Investments Limited <Wrap Services A/C> | 409,313 | 0.63% |
| Custodial Services Limited <Beneficiaries Holding A/C> | 173,365 | 0.27% |
| Mr Christopher Graham Roberts | 172,387 | 0.26% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 143,218 | 0.22% |
| HSBC Custody Nominees (Australia) Limited i | 118,811 | 0.18% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 109,295 | 0.17% |
| Netwealth Investments Limited <Super Services A/C> | 102,259 | 0.16% |
| BNP Paribas Noms (NZ) Ltd | 97,595 | 0.15% |
| HSBC Custody Nominees (Australia) Limited GSCO ECA | 96,146 | 0.15% |
| IOOF Investment Services Limited <IPS Superfund A/ C> | 90,817 | 0.14% |
| Citicorp Nominees Pty Limited <143212 Nmmt Ltd A/ C> | 61,690 | 0.09% |